Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

被引:24
作者
Cortesi, Laura [1 ]
Piombino, Claudia [1 ]
Toss, Angela [1 ]
机构
[1] Univ Hosp Modena, Dept Oncol & Haematol, Genet Oncol Unit, I-41125 Modena, Italy
关键词
BRCA1; BRCA2; PALB2; homologous recombination repair; METASTATIC BREAST-CANCER; DNA-DAMAGE RESPONSE; HEREDITARY BREAST; OVARIAN-CANCER; MAINTENANCE THERAPY; DOUBLE-BLIND; PHASE-II; ATM; WOMEN; RISK;
D O I
10.3390/jpm11040245
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and PALB2 are also involved. BRCA1/2 germline mutations are targeted by PARP inhibitors. The aim of this commentary is to explore whether germline mutations in HRR-related genes other than BRCA1/2 have to be considered as prognostic factors or predictive to therapies by discussing the results of two articles published in December 2020. The TBCRC 048 trial published by Tung et al. showed an impressive objective response rate to olaparib in metastatic breast cancer patients with germline PALB2 mutation compared to germline ATM and CHEK2 mutation carriers. Additionally, Yadav et al. observed a significantly longer overall survival in pancreatic adenocarcinoma patients with germline HRR mutations compared to non-carriers. In our opinion, assuming that PALB2 is a high-penetrant gene with a key role in the HRR system, PALB2 mutations are predictive factors for response to treatment. Moreover, germline mutations in the ATM gene provide a better outcome in pancreatic adenocarcinoma, being more often associated to wild-type KRAS. In conclusion, sequencing of HRR-related genes other than BRCA1/2 should be routinely offered as part of a biological characterization of pancreatic and breast cancers.
引用
收藏
页数:10
相关论文
共 61 条
[1]   Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination [J].
Buisson, Remi ;
Dion-Cote, Anne-Marie ;
Coulombe, Yan ;
Launay, Helene ;
Cai, Hong ;
Stasiak, Alicja Z. ;
Stasiak, Andrzej ;
Xia, Bing ;
Masson, Jean-Yves .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (10) :1247-+
[2]   The Fanconi anaemia pathway: newyplayers and new functions [J].
Ceccaldi, Raphael ;
Sarangi, Prabha ;
D'Andrea, Alan D. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2016, 17 (06) :337-349
[3]   Playing the End Game: DNA Double-Strand Break Repair Pathway Choice [J].
Chapman, J. Ross ;
Taylor, Martin R. G. ;
Boulton, Simon J. .
MOLECULAR CELL, 2012, 47 (04) :497-510
[4]   The DNA Damage Response: Making It Safe to Play with Knives [J].
Ciccia, Alberto ;
Elledge, Stephen J. .
MOLECULAR CELL, 2010, 40 (02) :179-204
[5]  
Cohen Stephanie A, 2019, Am Soc Clin Oncol Educ Book, V39, pe34, DOI 10.1200/EDBK_238937
[6]   Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Coleman, Robert L. ;
Oza, Amit M. ;
Lorusso, Domenico ;
Aghajanian, Carol ;
Oaknin, Ana ;
Dean, Andrew ;
Colombo, Nicoletta ;
Weberpals, Johanne, I ;
Clamp, Andrew ;
Scambia, Giovanni ;
Leary, Alexandra ;
Holloway, Robert W. ;
Amenedo Gancedo, Margarita ;
Fong, Peter C. ;
Goh, Jeffrey C. ;
O'Malley, David M. ;
Armstrong, Deborah K. ;
Garcia-Donas, Jesus ;
Swisher, Elizabeth M. ;
Floquet, Anne ;
Konecny, Gottfried E. ;
McNeish, lain A. ;
Scott, Clare L. ;
Cameron, Terri ;
Maloney, Lara ;
Isaacson, Jeff ;
Goble, Sandra ;
Grace, Caroline ;
Harding, Thomas C. ;
Raponi, Mitch ;
Sun, James ;
Lin, Kevin K. ;
Giordano, Heidi ;
Ledermann, Jonathan A. .
LANCET, 2017, 390 (10106) :1949-1961
[7]   An Overview of PARP Inhibitors for the Treatment of Breast Cancer [J].
Cortesi, Laura ;
Rugo, Hope S. ;
Jackisch, Christian .
TARGETED ONCOLOGY, 2021, 16 (03) :255-282
[8]   CHEK2 is a multiorgan cancer susceptibility gene [J].
Cybulski, C ;
Górski, B ;
Huzarski, T ;
Masojc, B ;
Mierzejewski, M ;
Debniak, T ;
Teodorczyk, U ;
Byrski, T ;
Gronwald, J ;
Matyjasik, J ;
Zlowocka, E ;
Lenner, M ;
Grabowska, E ;
Nej, K ;
Castaneda, J ;
Medrek, K ;
Szymanska, A ;
Szymanska, J ;
Kurzawski, G ;
Suchy, J ;
Oszurek, O ;
Witek, A ;
Narod, SA ;
Lubinski, J .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (06) :1131-1135
[9]   Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer [J].
Cybulski, Cezary ;
Wokolorczyk, Dominika ;
Jakubowska, Anna ;
Huzarski, Tomasz ;
Byrski, Tomasz ;
Gronwald, Jacek ;
Masojc, Bartlomiej ;
Debniak, Tadeusz ;
Gorski, Bohdan ;
Blecharz, Pawel ;
Narod, Steven A. ;
Lubinski, Jan .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) :3747-3752
[10]   Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment [J].
Desmond, Andrea ;
Kurian, AllisonW. ;
Gabree, Michele ;
Mills, Meredith A. ;
Anderson, Michael J. ;
Kobayashi, Yuya ;
Horick, Nora ;
Yang, Shan ;
Shannon, Kristen M. ;
Tung, Nadine ;
Ford, JamesM. ;
Lincoln, Stephen E. ;
Ellisen, Leifw. .
JAMA ONCOLOGY, 2015, 1 (07) :943-951